The TWiST analysis of the phase III ENGOT-OV16/NOVA trial evaluated the time without symptoms or toxicity for niraparib vs placebo in patients with recurrent ovarian cancer.
Cancer Network spoke with Charles Shapiro, MD, about the USPSTF's stance on use of tamoxifen, raloxifene, and aromatase inhibitors to prevent breast cancer.
The final results of the LNH-PRO-05 study showed that a combination of antiproliferative and immunomodulatory agents with chemo had good outcomes in follicular lymphoma patients.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: UBM Medica, a divsion of UBM Americas
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA
